Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept.
OBJECTIVE
Dickkopf-1 (Dkk-1) regulates bone remodeling in animal models of inflammatory arthritis, but its role in patients with rheumatoid arthritis (RA) remains unclear.


METHODS
Baseline circulating Dkk-1 was measured in 113 patients with RA (< 3 yrs) who received etanercept (10 or 25 mg twice/week, n = 63) or methotrexate alone (n = 40) for 1 year. Progression was assessed by changes in radiological Sharp score.


RESULTS
Increased Dkk-1 was associated with a higher risk of progression of bone erosion, independently of age, sex, baseline radiological damage, C-reactive protein, and disease activity in patients treated with etanercept.


CONCLUSIONS
Dkk-1 may be an important mediator of bone erosion in patients with RA.
INSERM Research Unit 664, Lyon, France. patrick.garnero@synarc.com
Patrick
P
Garnero
Nadine Charni-Ben
NC
Tabassi
Nathalie
N
Voorzanger-Rousselot
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012306:Risk; D012720:Severity of Illness Index
D018501:Antirheumatic Agents; C501126:DKK1 protein, human; D007074:Immunoglobulin G; D007155:Immunologic Factors; D036341:Intercellular Signaling Peptides and Proteins; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate